von Laffert, M <br/><br/>
ALK-Testing in non-small cell lung cancer (NSCLC): Immunohistochemistry (IHC) and/or fluorescence in-situ Hybridisation (FISH)?: Statement of the Germany Society for Pathology (DGP) and the Working Group Thoracic Oncology (AIO) of the German Cancer Society e.V. (Stellungnahme der Deutschen Gesellschaft für Pathologie und der AG Thorakale Onkologie der Arbeitsgemeinschaft Onkologie/Deutsche Krebsgesellschaft e.V.).  [electronic resource] 

 -  Lung cancer (Amsterdam, Netherlands)  01 2017 
 - 1-5 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1872-8332 
<br/><br/><label>Standard No.: </label>10.1016/j.lungcan.2016.11.008  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Algorithms<br/>Anaplastic Lymphoma Kinase<br/>Carcinoma, Non-Small-Cell Lung--genetics<br/>Crizotinib<br/>Disease Progression<br/>Gene Rearrangement<br/>Germany<br/>Humans<br/>Immunohistochemistry--methods<br/>In Situ Hybridization, Fluorescence--methods<br/>Lung Neoplasms--genetics<br/>Oncogene Proteins, Fusion--genetics<br/>Protein Kinase Inhibitors--therapeutic use<br/>Pyrazoles--therapeutic use<br/>Pyridines--therapeutic use<br/>Receptor Protein-Tyrosine Kinases--genetics<br/>Survival<br/>Translocation, Genetic